Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cancer Immunology, Immunotherapy
Published in: Cancer Immunology, Immunotherapy 2/2001

01-05-2001 | ORIGINAL ARTICLE

Targeting properties of an anti-CD16/anti-CD30 bispecific antibody in an in vivo system

Authors: Christoph Renner, Ingo Stehle, Fook Thean Lee, Cathrine Hall, Bruno Catimel, Edouard C. Nice, Angela Mountain, Angela Rigopoulos, Martin W. Brechbiel, Michael Pfreundschuh, Andrew M. Scott

Published in: Cancer Immunology, Immunotherapy | Issue 2/2001

Login to get access
Metadata
Title
Targeting properties of an anti-CD16/anti-CD30 bispecific antibody in an in vivo system
Authors
Christoph Renner
Ingo Stehle
Fook Thean Lee
Cathrine Hall
Bruno Catimel
Edouard C. Nice
Angela Mountain
Angela Rigopoulos
Martin W. Brechbiel
Michael Pfreundschuh
Andrew M. Scott
Publication date
01-05-2001
Publisher
Springer-Verlag
Published in
Cancer Immunology, Immunotherapy / Issue 2/2001
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s002620100172

Other articles of this Issue 2/2001

Cancer Immunology, Immunotherapy 2/2001 Go to the issue

ORIGINAL ARTICLE

Active idiotypic vaccination in a patient with biclonal follicular lymphoma

ORIGINAL ARTICLE

Human scFv antibody fragments specific for the epithelial tumour marker MUC-1, selected by phage display on living cells

ORIGINAL ARTICLE

Expression of L-selectin and efficient binding to high endothelial venules do not modulate the dissemination potential of murine B-cell lymphoma

ORIGINAL ARTICLE

Long-term treatment with low doses of interleukin-2 and interferon-α: immunological effects in advanced renal cell cancer

ORIGINAL ARTICLE

Generation of human anti-MUC3 IgG antibodies after in vitro immunization of naive peripheral blood B-lymphocytes

ORIGINAL ARTICLE

Tributyrin enhances the cytotoxic activity of interleukin-2/interleukin-12 stimulated human natural killer cells against LS 174T colon cancer cells in vitro
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits